Tivozanib Publications & Presentations | AVEO Oncology

Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.


September 29, 2020
PublicationTivozanib

TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

Authors: L. Albiges, P. Barthélémy, M. Gross-Goupil, S. Negrier, M. N. Needle, B. Escudier. Click here for link to article.

September 13, 2020
PublicationTivozanib

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Authors: Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, Daniel Powers, David F. McDermott, Brian I. Rini. Click here for link to article.

May 29, 2020
PresentationTivozanib

ASCO 2020: TIVO-3: Final OS analysis of a randomized, controlled, multi-center, open-label phase 3 study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC)

December 24, 2019
PublicationTivozanib

Real-World Results from One Year of Therapy with Tivozanib

Authors: Michael Staehler, Annabel K. Spek, Severin Rodler, Melanie Schott, Jozefina Casuscelli, Lena Mittelmeier, Marcus Schlemmer. Click here for link to article.

November 16, 2019
PresentationTivozanib

KCS 2019: TIVO-3: A Phase 3 Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC): Overall Survival 2-Year Update

September 30, 2019
PresentationTivozanib

ESMO 2019: TiNivo: Tivozanib Combined With Nivolumab Results in Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma (mRCC) – Final Results

1 3 4 5 6 7 12